Skip to content
Menu

Globus Medical, Inc. GMED

Full chart Compare
Set alert

Price alert · GMED

All alert types
69.99 USD -0.51 (-0.72%)

Regular-session close

69.99 0.00 0.00%

After hours · Nov 17, 5:25 PM ET

69.49 Day range 70.89
69.49 52-week range 101.40
YTD
-19.84%
1 year
-16.32%
Market cap
9.27B
Revenue (ttm)
3.14B
Profit margin
17.76%
EPS (ttm)
4.03
Shares out
110.04M
P/E ratio
17.37
Forward P/E
13.12
YTD return
-19.84%
1-year return
-16.32%
50-day average
76.40
Volume
1.14M
Avg volume
1.61M
Open
70.25
Previous close
70.50
Day's range
69.49 – 70.89
52-week range
69.49 – 101.40
Beta
0.95
Analysts
Buy
Price target
93.43 (+33.5%)
Earnings date
Feb 23, 2027

5D -4.72 (-6.32%)

70727476WedThuFriMonTue69.99

Key statistics

200-day average
82.60
Enterprise value
8.93B
PEG ratio
2.76
Price / sales
2.95
Price / book
1.94
Revenue growth
-0.70%
Free cash flow
509.87M
Total cash
517.44M
Total debt
108.19M
Return on equity
12.13%
Short % of float
8.64%

Fundamental scorecard

19 of 25 checks passed on GMED’s reported financials

ValueGrowthProfitabilityHealthDividend

19of 25 checks passed

  • Value 5 of 5
  • Growth 5 of 5
  • Profitability 4 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
GMED Revenue — quarterly 763.72M
GMED Net income — quarterly 141.17M
GMED EPS — quarterly 1.05

Earnings

GMED recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 23, 2027Dec 30, 20261.30———
Nov 5, 2026Sep 30, 20261.201.23+0.03+2.50%
Aug 6, 2026Jun 30, 20261.101.34+0.24+21.82%
May 7, 2026Mar 31, 20260.921.12+0.20+21.74%
Feb 24, 2026Dec 31, 20251.061.28+0.22+20.75%
Nov 6, 2025Sep 30, 20250.7811.18+0.40+51.09%

Upgrades / downgrades

GMED analyst upgrades and downgrades
DateFirmActionFromTo
Nov 9, 2026Truist SecuritiesmainBuyBuy
Nov 6, 2026Canaccord GenuitymainBuyBuy
Nov 6, 2026Wells FargomainOverweightOverweight
Nov 6, 2026NeedhammainBuyBuy
Nov 6, 2026BMO CapitaldownOutperformMarket Perform
Oct 1, 2026RBC CapitalmainOutperformOutperform

About Globus Medical, Inc.

Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices; treatment options for motion preservation technologies consisting of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and biologic solutions, such as allografts and synthetic alternatives. It also provides orthopedic trauma solutions, including limb reconstruction, fracture plating, intramedullary nailing, external fixation, and compression screw technologies; hip and knee arthroplasty solutions, including modular cement and cementless hip stems, acetabular cups, femoral heads, highly cross-linked liners, partial knee systems, cruciate retaining, posterior stabilized, and revision options; spinal cord stimulation services; and neuromonitoring services, which provide onsite and remote monitoring of the neurological systems. In addition, the company offers ExcelsiusGPS platform, a robotic guidance and navigation system for minimally invasive and open procedures; Surgimap, a surgical planning software platform; Excelsius3D, a platform combined with ExcelsiusGPS that provides an intraoperative and image-guided robotic navigation solution; ExcelsiusHub, which provides real-time patient array monitoring, tissue sparing drills, and registration flexibility; and ExcelsiusFlex, a total knee arthroplasty robotic solution. Further, it distributes human cells, tissues, and cellular and tissue-based products. The company sells its products through direct and distributor sales representatives; and independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on GMED — it syncs with the Stock Master app.

Insider holders

GMED insider holders
InsiderRelationLatest transactionDateShares held
DAVIDAR DAVID DDirectorStock GiftJul 26, 2026673,642
KLINE KYLEChief Financial OfficerSaleJan 7, 20260
LEMAITRE DANIELDirectorSaleNov 21, 20240
NORWALK LESLIE VDirectorSaleJan 7, 202610,419
PAUL DAVID COfficer, Director and Beneficial OwnerConversion of Exercise of derivative securityDec 7, 202560,417
PFEIL KEITH W.Chief Operating OfficerSaleJan 9, 20250

Institution ownership

GMED institution ownership
Holder% heldSharesValueReported
Blackrock Inc.9.91%10,906,047763.64MSep 29, 2026
Janus Henderson Group Ltd.7.85%8,634,195604.57MSep 29, 2026
Vanguard Capital Management LLC4.61%5,075,559355.39MSep 29, 2026
Vanguard Portfolio Management LLC4.42%4,866,366340.74MSep 29, 2026
State Street Corporation3.38%3,718,553260.37MSep 29, 2026
Boston Partners3.10%3,415,554239.16MSep 29, 2026

Fund ownership

GMED fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Mid-Cap ETF3.62%3,983,485278.92MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.27%3,595,564251.76MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.36%2,597,815181.90MJun 29, 2026
JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund2.10%2,313,088161.96MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund1.36%1,496,500104.78MJun 29, 2026
J.P. Morgan Fleming Mutual Fd. Group, Inc.-JPMorgan Mid Cap Value Fd.1.34%1,475,978103.35MJun 29, 2026